EGF receptors in urological cancer. Molecular basis and therapeutic involvements;Récepteurs EGF dans les cancers urologiques. Bases moléculaires et implications thérapeutiques

Annales de Medecine Interne

Volumn 154, Issue 7, 2003, Pages 448-456

  Paule, Bernard ^a   Brion, Nathalie ^b  

^a HENRI MONDOR HOSPITAL   (France)

^b CENTRE HOSPITALIER DE VERSAILLES   (France)

Author keywords

Epidermal growth factor receptor (EGFR); Urologic cancer

Indexed keywords

BICALUTAMIDE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GEFITINIB; MONOCLONAL ANTIBODY; PACLITAXEL;

BLADDER CANCER; CELL PROLIFERATION; DISEASE ASSOCIATION; DRUG MECHANISM; GENE OVEREXPRESSION; HUMAN; KIDNEY CARCINOMA; MULTIMODALITY CANCER THERAPY; PROGNOSIS; PROSTATE CANCER; REVIEW; URINARY TRACT CANCER;

GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; UROLOGIC NEOPLASMS;

EID: 1642471656     PISSN: 0003410X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. GULLICK WJ: Prevalence of aberrant expression of the epidermal growth factor receptors in human cancers. Br Med J, 1991; 47: 87-98.
2. SIEGMUND MJ, YAMAZAKI H, PASTAN L: Interleukin-6 in prostate carcinoma cells. Cancer Res, 1990; 50: 7786-8.
3. YARDEN Y, ULBRICH A: Growth factor receptor tyrosine-kinase. Annu Rev Biochim, 1988; 7: 443-78.
4. GROBB MH: MAP kinase pathways. Proj Biophy Mol Biol, 1999; 71: 479.
5. DAVID M, WONG L, FLAVELL R, THOMPSON SA, WELLS A, LARNER AC, et al.: STAT activation by epidermal growth factor (EGFr and amphiregulin) Requirement for the EGF receptor kinase but not for tyrosine phosphorylation sites or JAK1. J Biol Chem, 1996; 271: 9185-8.
6. LEAMAN DW, LEUNG S, LI X, STARK GR: Regulation of STAT-dependant pathways by growth factors and cytokine. FASEB J, 1996; 10: 1578-88.
7. PARK OK, SHAEFER TS, NATHANS D: In vitro activation of STAT 3 by epidermal growth factor receptor kinase. Proc Natl Acad Sci USA, 1996; 93: 13704-8.
8. ZHONG Z, WEN Z, DARNELL JE Jr: Stat 3: STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science, 1994; 264: 95-8.
9. GARCIA R, YU CL, HUDNALL A, CATLETT R, NELSON KL, SMITHGALE T, et al.: Constitutive activation of STAT 3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ, 1997; 8: 1267-76.
10. GRANDIS RJ, DRENNING SD, CHAKRABORTY A, ZHOU MY, ZENG Q, PITT AS, et al.: Requirement of STAT 3 but not STAT 1 activation by epidermal growth factor receptor-mediated cell growth in vitro. J Clin Invest, 1998; 102: 1385-92.
11. COFFER PJ, JIN J, WOODJETT JR: Protein kinase B (c-Akt): a multifunctional activation of phosphatidylinositol 3-kinase activation. Biochem, 1998; 335: 1-12.
12. WOODBURN JR: The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther, 1999; 82: 241-50.
13. GRANDIS JR, ZENG Q, DRENNING SD: Epidermal growth factor mediated STAT 3 signaling blocks apoptosis in head and neck cancer. Laryngoscope, 2000; 110: 808-74.
14. CATLETT-FALCONE R, LANDOWSKI T, OSHIRO MM, TURKSON J, LEVITZKII A, SAVINO R, et al.: Constitutive activation of STAT 3 signaling confers resistance to apoptosis in human UR 66 myeloma cells. Immunity, 1999; 10: 105-15.
15. DICKSTEIN BM, VALVERIUS EM, WOSIKOWSKI K, SACEDA M, PEARSON JW, MARTIN MB, et al.: SE. Increased epidermal growth factor receptor in an estrogen-responsive adriamycin resistance MCF-7 cell line. J Cell Physiol, 1993; 157: 110-8.
16. DICKSTEIN BM, WOSIKOWSKI K, BATES SE: Increased resistance to cytotoxic agents in ZR758 human breast cancer cells transfected with epidermal growth factor receptor. Mol Cell Endocrinol, 1995; 110: 205-11.
17. TSAI CM, LEVITZKI A, Vu LH, CHANG KT, CHEN GCC, GAZIT A, et al.: Enhancement of chemosensitivity by tyrphostin AG 825 in high-p185 neu expressing non small cell lung cancer cells. Cancer Res, 1996; 56: 1068-74.
18. JORDA M, MORALES A, GHORAB Z, FERNANDEZ G, NADJI M, BLOCK N: HER-2 expression in prostatic cancer: a comparison with mammary carcinoma. J Urol, 2002; 168: 1412-4.
19. SANCHEZ KM, SWEENEY C, MASS R, KOCH M, ECKERT GI, GEARY NA, et al.: Evaluation of HER-2/neu expression in prostatic adenocarcinoma: a request for a standardized organ specific methodology. Cancer, 2002; 95: 650-5.
20. FAN Z, BASELGA J, MASUI H, MENDELSOHN J: Antitumoral effect of epidermal growth factor receptor monoclonal antibodies plus cis-diaminochloroplatinum on well established A 431 cell xenografts. Cancer Res, 1993; 53: 4637-62.
21. MENDELSOHN J, BASELGA J: The EGF receptor family as targets for cancer therapy. Oncogene, 2000; 10: 6550-85.
22. CIARDIELLO F, BIANCO R, DAMIANO V, DELORENZO S, PEPE S, DE PLACIDO S, et al.: Antitumoral activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res, 1999; 5: 909-16.
23. INOUE K, SLATON JW, PERROTTE F, DAVIS DW, BRUNS CJ, HICKLIN DJ, et al.: Paclitaxel enhances the effects of the antiepidermal growth factor receptor monoclonal antibody by Imclone C 225 in mice with metastatic bladder transitional cell carcinoma. Clin Cancer Res, 2000; 6: 4874-84.
24. BRUNS CJ, HARBISON MT, DAVIES DW, PORTERA CA, YSAN R, MC CONKEY DJ, et al.: Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenesis mechanisms. Clin Cancer Res, 2000; 6: 1936-48.
25. MILAS L, MASON K, HUNTER N, PETERSEN S, YAMAKAWA M, ANG K, et al.: In vitro enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res, 2000; 6: 701-5.
26. WOLLMAN R, YAHALMON J, MAXY R, PINTO J, FUKS Z: Effect of epidermal growth factor and radiation sensitivity of human breast cancer in vitro. Int J Radiat Oncol Biol Phys, 1994; 30: 91-8.
27. BALABAR N, MONI J, SHANNON M, DANG L, MUTPHY E, GOLDBORN T: The effect of ionizing radiation on signal transduction antibodies to EGF receptor sensitivity A 461 cells to radiation. Biochem Biopys Acta, 1996; 1314: 147-56.
28. HUANG SM, BOCK JM, HARARI PM: Epidermal growth factor receptor blockade with C 225 modulates proliferation apoptosis and radiosensitivity in squamous cell carcinoma of the head and neck. Clin Cancer Res, 1999; 59: 1935-40.
29. HUANG SM, HARARI PM: Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinoma: inhibition of damage repair cell cycle kinetics and tumor angiogenesis. Clin Cancer Res, 2000; 6: 2106-74.
30. BONNER JA, EZECKIEL HP, ROBERT F, MEREDITH F, SPENCER SA, WAKSAI HW: Continued response following treatment with IMC-C225 an EGFr moAb combined with RT in advanced head and neck malignancies. Proc Am Soc Clin Oncol, 2000; 19: 4a (abstract 5F).
31. GRANDIS RJ, DRENNING SD, ZENG Q, WATKINS SC, MELHEM MF, ENDO S, et al.: Constitutive activation of STAT 3 signaling abrogate apoptose in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci USA, 2000; 97: 4227-32.
32. BASELGA J: New therapeutic agents targeting the EGFR. J Clin Oncol, 2000; 18 (suppl): 545-90.
33. SIROTNAK FM, ZAKOWSKY MF, MILLER VA, SCHER HJ, KRIS MG: Efficacy of cytotoxic agents against human tumor xenografts in markedly enhanced by coadministration of ZD 1839 (Iressa) an inhibitor of EGFR tyrosine-kinase. Clin Cancer Res, 2000; 12: 4885-92.
34. HARARI PM, HUANG SM: Modulation of molecular targets to enhance radiation. Clin Cancer Res, 2000; 6: 313-25.
35. BIANCO C, TORTORA G, BIANCO R, CAPUTO R, VENEZIANI BM, DAMIANO V, TROIANI T, et al.: Enhancement of antitumoral activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine-kinase inhibitor ZD1839 (Iressa). Clin Cancer Res, 2002; 8: 3250-8.
36. ISHIKAWA J, MAEDA S, UMGU K, UMEZU K, SIGIYAMA T, KAMIDONO S: Amplification and overexpression of the epidermal growth factor receptor gene in human renal-cell carcinoma. Int J Cancer, 1990; 45: 1018-21.
37. UHLMAN DL, NGUYEN P, MANIVEL JC, ZHANG G, HAGEN K, FRALEY E, et al.: Epidermal gowth factor receptor and transforming growth factor alpha expression in papillary and non papllary renal cell carcinoma; correlations with metastatic behavior and prognosis. Clin Cancer Res, 1995; 1: 913-20.
38. STUMM G, EBERWEIN S, ROSTOCK-WOLF S, STEIN H, POMER S, SCHLEGEL J, et al.: Concomitant overexpression of the EGFR and erb-B2 genes in renal cell carcinoma (RCC) is correlated with dedifferentiation and metastasis. Int J Cancer, 1996; 69: 17-22.
39. PAULE B, BELLOT J, RUDANT C, COULOMBEL C, ABBOU CC: Importance of IL-6 expression in primary human renal cell carcinoma: an immunohistochemical study. J Clin Pathol, 2000; 53: 388-90.
40. COSTES V, LIAUTARD J, PICOT MC, ROBERT M, LEQUEUX N, BROCHIER J, et al.: Expression of the interleukin 6 receptor in primary renal cell carcinoma. J Clin Pathol, 1997; 50: 835-40.
41. PAULE B, CLERC D: Cancer du rein: métastases osseuses, immunothérapie et interleukine 6. Ann Med Interne, 1999; 150: 4-9.
42. PAULE B: Interleukine-6 et métastases osseuses du cancer du rein: bases moléculaires et implications thérapeutiques. Prog Urol, 2001; 11: 368-75.
43. PAULE B, CLERC D, RUDANT C, COULOMBEL C, BONHOMME-FAIVRE L, QUILLARD J, et al.: Enhanced expression of interleukin-6 in bone and serum of metastatic renal cell carcinoma. Hum Pathol 1998; 29: 421-4.
44. CIARDIELLO F, DAMIANO V, BIANCO R, BIANCO C, FONTANINI G, DE LAURENTIS M, et al.: Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. J Natl Cancer Inst, 1996; 88: 1170-6.
45. CIARDIELLO F, CAPUTO R, BIANCO R, DAMIANO V, POMATICO G, PEPE S, et al.: Cooperative inhibition of renal cancer growth by anti-EGF receptor antibodies and protein kinase A anti-senses oligonucleotides. J Natl Cancer Inst, 1998; 90: 1087-94.
46. DRUCKER BJ, SCHWARTZ L, MARION S, MOTZER R: Phase II trial of ZD 1839 (Iressa) an EGF receptor inhibitor in patients with advanced renal cell carcinoma. Proc Am Soc Clin Oncol, 2002; Abstract 720, 181a.
47. JIMENEZ RE, GRIGNON DJ, VARSHAM-PAYAN M, HUSSAIN M: Analysis of HER-2/ neu overexpression in primary and metastatic transitional cell carcinoma of the bladder. Proc Am Soc Clin Oncol, 2000; Abstract 1294, 329a.
48. BAJORIN DF, MCCAFFREY JA, DODD PM, HILTON S, MAZUMDAR M, KELLY WYT, et al.: Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract. Cancer, 2002; 88: 1671-8.
49. BELLMUNT J, GUILLEM V, PAZ-ARES L, GONZALES-LARRIBA JL, CARLES J, BATISTE-ALENTOM E, et al., FOR THE SPANISH ONCOLOGY GENITOURINARY GROUP: Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. J Clin Oncol, 2000; 18: 3247-55.
50. CONNOLLY JM, ROSE DP: Autocrine regulation of DU 145 human cancer cell growth by epidermal growth-related peptide. Prostate, 1991; 19: 173-80.
51. YANG Y, CHISHOLM GD, HABIB FK: Epidermal growth factor and transforming growth factor a concentration in BPH and cancer of the prostate: their relation ships and tissue androgen levels. Br J Cancer, 1993; 67: 152-5.
52. DERYNCK R: Transforming growth factor-a. Cell, 1988; 54: 593-7.
53. HARPER ME, GODDARD L, GLYNNE-JONES E, WILSON DW, PRICE-THOMAS M, PEELING WB, et al.: An immunocytochemical analysis of TGF-a expression in benign and malignant prostate tumors. Prostate, 1993; 23: 9-23.
54. CIARDELLO F, DI LORENZO G, TORTORA G, D'ARMIENTO F, DE ROSA G, ANTORINO R, et al.: Expression of epidermal growth factor receptor (EGFR) correlates with disease and progression to androgen-independence in tumor prostate cancer. Proc Am Soc Clin Oncol, 2002; Abstract 701,176a.
55. ZHAU HE, WAN DS, ZUOU J, MILLER GJ, VON ESCHENBACH AC: Expression of c-erbB2/neu protooncogene in human prostatic cancer tissues and cell lines. Mol Carcinog, 1992; 5: 320-7.
56. AREU Y, TATSHURIO T, YOSHIDA O: CerbB-2 oncoprotein: a potential biomarker of advanced prostate cancer. Prostate, 1997; 30: 195-201.
57. SIGNORETTI S, MONTIRONI R, MANOLA J, ALTIMARI A, TAM C, BUBLEY G, et al.: Her-2-neu expression and progression toward androgen independance in human prostate cancer. J Natl Cancer Inst, 2000; 92: 1918-25.
58. KALLAKURY BV, SHEEHANCE CE, AMBROS RA, FISHER MA, KAUFMAN RP Jr, MURACA PJ, et al.: Correlation between p 34 cdc 2 cyclin-dependant kinase over expression, CD 44s dowregulation and HER-2-neu oncogene amplification with recurrence in prostate adenocarcinoma. J Clin Oncol, 1998; 16: 1302-9.
59. GROSSMAN ME, HUANG H, TINDALL DJ: Androgen receptor signaling in androgen refractory prostate cancer. J Natl Cancer Inst, 2001; 93: 1687-97.
60. CRAFT N, SHOSTAK Y, CAREY M, SAWYERS CL: A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signalling by the HER-2/neutyrosine-kinase. Nat Med, 1999; 5: 280-5.
61. YEH S, LIN HK, KANG HY, THIN TH, LIN MF, CHANG C: From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci USA, 1999; 96: 5458-63.
62. YU D, JING T, LIU B, YAO J, TAN M, MCDONNEL TJ, et al.: Overexpression of C erb B2 blocks taxol induced apoptosis by upregulation of p21 Cip1 which inhibits p34 cdc2 kinase. Mol Cell, 1998; 2: 581-92.
63. BASELGA J, TRIPATHY D, MENDELSOHN J, BAUGHMAN S, BENZ C, DANTIS L, et al.: Phase II study of weekly intravenous recombinant humanized anti-p185 HER 2 monoclonal antibody in patients with HER2/neu overexpressing metastatic breast cancer. J Clin Oncol, 1996; 14: 737-44.
64. GIRI D, OZEN M, ITTMANN M: Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol, 2001; 59: 2159-65.
65. HOOSEN N, ABDUL M, MC CABE R, GERO E, DEFTOS L, BANKS M, et al.: Clinical significance of elevation in neuroendocrine factors and interleukin 6 in metastatic prostate cancer. Urol Oncol, 1995; 7: 249-51.
66. LOU W, NI Z, DYER K, TWEARDY DJ, GAO AC: Interleukin-6 induces prostate cancer cell growth accompagnied by activation of STAT 3 signalling. Prostate, 2000; 42: 239-42.
67. QIU Y, RAVI L, KUNG HJ: Requierement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells. Nature, 1998; 393: 83-8.
68. CAMPBELL CL, JIANG Z, SAVARESE DM, SAVARESE TM: Increased expression of the interleukin-11 receptor and evident STAT 3 activation in prostatic carcinoma. Am J Pathol, 2001; 158: 25-32.
69. PREWETT M, ROCKWELL P, ROCKWELL RF, GIORGIO NA, MENDELSOHN J, SHER HI, et al.: The biologic effects of C 225 a chimeric monoclonal antibody to the EGFR on human prostate carcinoma. J Immunother Emphasis Tumor Immunol, 1996; 19: 419-27.
70. PENG D, FAN Z, LU Y, DEBLASIO T, SCHER H, MENDELSOHN J: Anti-epidermal growth factor receptor monoclonal antibody C 225 upregulation P 27 KIP1 and induces G1 arrest in prostatic carcinoma cell line DU 145. Cancer Res, 1996; 56: 3666-4.
71. SIROTNAK FM, SHE Y, LEE F, CHEN J, SHER HL: Studies with CWR22 xenografts in nude mice suggest that ZD 1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer. Clin Cancer Res, 2002; 8: 3870-6.
72. CHRISTENSEN JG, SCHRECK RD, CHAN E, WANG X, YANG C, LIU L, et al.: High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine-kinase inhibitors to inhibit EGFR phosphorylation in vivo. Clin Cancer Res, 2001; 7: 4230-8.
73. MOULDER SL, YAKES FM, MUTHUSWAMY SK, BIANCO R, SIMPSON JF, ARTEAGA CL: Epidermal growth factor receptor (HER1) tyrosine-kinase inhibitor ZD 1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res, 2001; 61: 8887-95.
74. AGUS DB, SCHER AI, HIGGINS B, FUX WD, HELLER G, FAZZARI M, et al.: Response of prostate cancer to anti-HER2/neu antibody in androgen-dependent and independent human xenograft models. Cancer Res, 1999; 59: 4761-4.
75. MELLINGHOFF IK, TRAN C, SAWYERS CL: Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine-kinase inhibitor PKI-166 on human prostate cancer xenografts. Cancer Res, 2002; 62: 5254-9.
76. MOASSER MM, BASSO A, AVERBUCH SD, ROSEN N: The tyrosine-kinase inhibitor ZD1839 (Iressa) inhibits HER-2 driven signalling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res, 2001; 61: 7184-8.
77. LANE HA, BEUVINK I, MOTOYAMA AB, DALY JM, NEVE RM, HYNES NE. ErbB2 potentiates breast tumor proliferation through modulation of p27 (Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol Cell Biol, 2000; 20: 3210-23.
78. TORTORA G, CAPUTO R, DAMIANO V, FONTANINI G, MELISI D, VENEZIANI BM, et al.: Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A and the epidermal growth factor receptor inhibitor iressa causes cooperative antitumor and antiangiogenic activity. Clin Cancer Res, 2001; 7: 4156-63.